Abstract 4400
Background
A strong scientific and public interest exists in the sustainability of pharmaceutical research and development and particularly the issue of anticancer drug prices. Despite of the number of publications, articles seem often opinion-based. To facilitate an evidence-based discourse, we reviewed the literature and produced an inventory of policy proposals. We then analyze the available quantitative evidence.
Methods
Due to the broad nature of the research question, a scoping review was performed. We combined multiple search strategies to get a systematic overview of the current body of literature.
Results
In total, we screened 4775 articles and categorized 23 proposals. 22 of 85 included articles used quantitative models. Overall, the quantitative evidence was inconclusive to deduct real world effects and evidence- based recommendations. We however identified promising solutions for further investigation: Royalty payments, prizes and rewards, two-part-pricing, price transparency, increased translational public research, and public clinical trials. At ESMO, we will present this list of promising solutions, their degree of disruptiveness and their empirical evidence. Furthermore, we will share feedback on selected solutions from a survey among European experts in the field of oncology and health regulation. Finally, we will discuss techniques of evidence based solutions facing high complexity and the need of additional data for choosing policy options.
Conclusions
Despite of the urgency of the matte of drug prices, we must realize that system consequences need careful considerations as implications for access and finances can be substantial. We advise testing promising solutions with experiments, dynamic simulations, and policy pilots.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4900 - Molecular profiling and prognostic significance of TP53 mutations in Diffuse Large B Cell Lymphoma: identifying a high-risk subgroup
Presenter: Yuan-Kai Shi
Session: Poster Display session 3
Resources:
Abstract
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract